Cardiff Oncology Inc (NASDAQ: CRDF) stock closed at $5.85 on 3/22/24 after a major increase of 13.8%. Moreover, above average trading volume at 140% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 8.3% during the last week.
Current PriceTarget Research Rating
CRDF is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Cardiff Oncology has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Cardiff Oncology has a very low Appreciation Score of 3 but a very high Power Rating of 92, and the Low Neutral Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment